Cargando…
Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases
The disease course of chronic lymphocytic leukemia (CLL) is frequently characterized by the occurrence of various complications, such as second primary cancer, which can impact patients’ prognoses. While therapies for CLL have evolved tremendously in the past decades, overlooking the possibility of...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947735/ https://www.ncbi.nlm.nih.gov/pubmed/35323322 http://dx.doi.org/10.3390/curroncol29030122 |
_version_ | 1784674510345076736 |
---|---|
author | Angotzi, Francesco Visentin, Andrea Scarmozzino, Federico Cellini, Alessandro Bertorelle, Roberta Pizzi, Marco Binotto, Gianni Dei Tos, Angelo Paolo Trentin, Livio |
author_facet | Angotzi, Francesco Visentin, Andrea Scarmozzino, Federico Cellini, Alessandro Bertorelle, Roberta Pizzi, Marco Binotto, Gianni Dei Tos, Angelo Paolo Trentin, Livio |
author_sort | Angotzi, Francesco |
collection | PubMed |
description | The disease course of chronic lymphocytic leukemia (CLL) is frequently characterized by the occurrence of various complications, such as second primary cancer, which can impact patients’ prognoses. While therapies for CLL have evolved tremendously in the past decades, overlooking the possibility of rare neoplasms that arise along with CLL may hinder the benefit that these therapies grant to patients. Moreover, the ability of newer therapies to alter the landscape of these complications is still largely unknown. Primary myelofibrosis (PMF) is not commonly associated with CLL, with only a few cases reported in the literature, with little information regarding the clinico-biological features and the optimal management for these associated conditions. Here, we report two unusual cases of PMF that occurred a few months after the start of therapy for CLL with targeted agents (ibrutinib and venetoclax). Both cases represented a diagnostic and therapeutic challenge, underscoring the need for clinicians to remain vigilant about the possible co-occurrence of these two hematological malignancies, especially in the era of targeted therapy for CLL. |
format | Online Article Text |
id | pubmed-8947735 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89477352022-03-25 Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases Angotzi, Francesco Visentin, Andrea Scarmozzino, Federico Cellini, Alessandro Bertorelle, Roberta Pizzi, Marco Binotto, Gianni Dei Tos, Angelo Paolo Trentin, Livio Curr Oncol Case Report The disease course of chronic lymphocytic leukemia (CLL) is frequently characterized by the occurrence of various complications, such as second primary cancer, which can impact patients’ prognoses. While therapies for CLL have evolved tremendously in the past decades, overlooking the possibility of rare neoplasms that arise along with CLL may hinder the benefit that these therapies grant to patients. Moreover, the ability of newer therapies to alter the landscape of these complications is still largely unknown. Primary myelofibrosis (PMF) is not commonly associated with CLL, with only a few cases reported in the literature, with little information regarding the clinico-biological features and the optimal management for these associated conditions. Here, we report two unusual cases of PMF that occurred a few months after the start of therapy for CLL with targeted agents (ibrutinib and venetoclax). Both cases represented a diagnostic and therapeutic challenge, underscoring the need for clinicians to remain vigilant about the possible co-occurrence of these two hematological malignancies, especially in the era of targeted therapy for CLL. MDPI 2022-02-27 /pmc/articles/PMC8947735/ /pubmed/35323322 http://dx.doi.org/10.3390/curroncol29030122 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Angotzi, Francesco Visentin, Andrea Scarmozzino, Federico Cellini, Alessandro Bertorelle, Roberta Pizzi, Marco Binotto, Gianni Dei Tos, Angelo Paolo Trentin, Livio Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases |
title | Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases |
title_full | Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases |
title_fullStr | Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases |
title_full_unstemmed | Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases |
title_short | Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases |
title_sort | primary myelofibrosis occurring during targeted therapy for chronic lymphocytic leukemia: a report of two cases |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947735/ https://www.ncbi.nlm.nih.gov/pubmed/35323322 http://dx.doi.org/10.3390/curroncol29030122 |
work_keys_str_mv | AT angotzifrancesco primarymyelofibrosisoccurringduringtargetedtherapyforchroniclymphocyticleukemiaareportoftwocases AT visentinandrea primarymyelofibrosisoccurringduringtargetedtherapyforchroniclymphocyticleukemiaareportoftwocases AT scarmozzinofederico primarymyelofibrosisoccurringduringtargetedtherapyforchroniclymphocyticleukemiaareportoftwocases AT cellinialessandro primarymyelofibrosisoccurringduringtargetedtherapyforchroniclymphocyticleukemiaareportoftwocases AT bertorelleroberta primarymyelofibrosisoccurringduringtargetedtherapyforchroniclymphocyticleukemiaareportoftwocases AT pizzimarco primarymyelofibrosisoccurringduringtargetedtherapyforchroniclymphocyticleukemiaareportoftwocases AT binottogianni primarymyelofibrosisoccurringduringtargetedtherapyforchroniclymphocyticleukemiaareportoftwocases AT deitosangelopaolo primarymyelofibrosisoccurringduringtargetedtherapyforchroniclymphocyticleukemiaareportoftwocases AT trentinlivio primarymyelofibrosisoccurringduringtargetedtherapyforchroniclymphocyticleukemiaareportoftwocases |